DBT–BIRAC Host 12th Webinar on Cell & Gene Therapy Advancements

21 Apr 2025 CW Team

With its transformative potential in treating complex and previously incurable diseases, Cell and Gene Therapy (CGT) is a priority area within the BioE3 vision to position India as a global leader in sustainable, high-performance biomanufacturing.

Highlights from the Webinar Dr Alka Sharma, Senior Adviser, DBT, opened the session by reiterating the BioE3 Policy’s mission to support green, high-impact biomanufacturing. She emphasised the need for strategic interventions to overcome sectoral challenges and drive growth in CGT innovation and accessibility.

Dr Kamakshi Chaithri, Scientist ‘D’, DBT, stressed the urgent need to prioritise this domain, particularly for life-threatening conditions like cancer and rare diseases. She outlined global and national positioning and underlined the DBT’s ongoing efforts to build a conducive innovation ecosystem for indigenous CGT development.

Dr Debojyoti Chakraborty, Principal Scientist at CSIR–IGIB, discussed cutting-edge gene editing technologies targeting sickle cell anaemia, ocular disorders, and more. He noted the regulatory and manufacturing bottlenecks and the importance of ensuring therapies are affordable and accessible.

Dr Anil Kamat, Head of Clinical Development, Immuneel Therapeutics, spoke on the commercial approval of CAR-T Cell therapy, supported by BIRAC. He discussed scale-up challenges and suggested solutions for improving access, affordability, and availability of CGTs.

The Department of Biotechnology (DBT), Government of India, in collaboration with BIRAC, held the 12th webinar under its Biomanufacturing and Biofoundry Initiative on 17th April 2025. Themed around “Cell and Gene Therapy”, the session falls under the Precision Biotherapeutics focus of the BioE3 (Biotechnology for Economy, Environment & Employment) Policy, which was approved by the Union Cabinet in August 2024. With its transformative potential in treating complex and previously incurable diseases, Cell and Gene Therapy (CGT) is a priority area within the BioE3 vision to position India as a global leader in sustainable, high-performance biomanufacturing. Highlights from the Webinar Dr Alka Sharma, Senior Adviser, DBT, opened the session by reiterating the BioE3 Policy’s mission to support green, high-impact biomanufacturing. She emphasised the need for strategic interventions to overcome sectoral challenges and drive growth in CGT innovation and accessibility. Dr Kamakshi Chaithri, Scientist ‘D’, DBT, stressed the urgent need to prioritise this domain, particularly for life-threatening conditions like cancer and rare diseases. She outlined global and national positioning and underlined the DBT’s ongoing efforts to build a conducive innovation ecosystem for indigenous CGT development. Dr Debojyoti Chakraborty, Principal Scientist at CSIR–IGIB, discussed cutting-edge gene editing technologies targeting sickle cell anaemia, ocular disorders, and more. He noted the regulatory and manufacturing bottlenecks and the importance of ensuring therapies are affordable and accessible. Dr Anil Kamat, Head of Clinical Development, Immuneel Therapeutics, spoke on the commercial approval of CAR-T Cell therapy, supported by BIRAC. He discussed scale-up challenges and suggested solutions for improving access, affordability, and availability of CGTs.

Infrastructure Energy

07 Oct 2025

Adani Green Adds 113 MW At Khavda, Capacity Hits 16.6 GW

Adani Green Energy Limited (AGEL) announced that it has operationalised 112.5 megawatts (MW) of renewable power projects at Khavda in Gujarat, raising its total generation capacity to 16,598.6 MW.The company said in an exchange filing that its step-down subsidiary, Adani Renewable Energy Fifty Six Limited, has commissioned a solar project of 87.5 MW, while Adani Green Energy Twenty Five B Limited has operationalised a 25 MW hybrid project at the same site.Following the required regulatory clearances, the company began power generation on 30 September 2025.With these additions, AGEL’s total o..

Infrastructure Energy

07 Oct 2025

Centre Sets National Standards For Renewable Power Use

The Central Government, in consultation with the Bureau of Energy Efficiency (BEE), has issued a new notification establishing minimum renewable energy consumption standards for designated power users across India. This framework replaces the 2023 notification and aims to accelerate the adoption of green electricity among consumers nationwide.Titled the Renewable Consumption Obligation (RCO), the regulation mandates that designated consumers — including electricity distribution licensees, open access consumers, and captive power users — must ensure a specified share of their total electric..

Infrastructure Energy

07 Oct 2025

Tata Power Signs Rs 12 Billion PPA For 80 MW Green Project

Tata Power Company announced that its renewable arm, Tata Power Renewable Energy Limited (TPREL), has signed a Power Purchase Agreement (PPA) with Tata Power Mumbai Distribution for an 80 MW Firm and Dispatchable Renewable Energy (FDRE) project.The Rs 12 billion project will combine solar, wind, and battery storage systems to provide reliable renewable power during peak demand periods, strengthening grid stability and meeting the growing energy needs of Mumbai.Scheduled for completion within 24 months, the facility is expected to generate around 315 million units (MUs) of clean electricity ann..